Evidence map›Paper›PMID 27120065›Full record

Trial reportInternational journal for parasitology. Drugs and drug resistance2015

Therapeutic effects of acetylspiramycin and garlicin on cryptosporidiosis among drug users.

Min-Zhu Huang, Jin Li, Lan Guan, Deng-Qing Li, Xin-Min Nie, Rong Gui, Xia Chen

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in International journal for parasitology. Drugs and drug resistance, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Pathogens (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Min-Zhu HuangDepartment of Epidemiology, School of Public Health, Changsha Medical University, Changsha 410219, China. Electronic address: huangminzhu_2002@163.com.
Jin LiThe Third Xiangya Hospital of Central South University, Changsha 410013, China. Electronic address: lincoln0221@126.com.
Lan GuanXiangya School of Medicine, Central South University, Changsha 410078, China. Electronic address: guanlan7@163.com.
Deng-Qing LiXiangya School of Medicine, Central South University, Changsha 410078, China. Electronic address: lidengqing@aliyun.com.
Xin-Min NieThe Third Xiangya Hospital of Central South University, Changsha 410013, China. Electronic address: niexinmin19840702@163.com.
Rong GuiThe Third Xiangya Hospital of Central South University, Changsha 410013, China. Electronic address: aguirong@163.com.
Xia ChenDepartment of Epidemiology, School of Public Health, Changsha Medical University, Changsha 410219, China. Electronic address: chen_1987_com@163.com.
Central South University · CNChangsha Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cryptosporidiosis affects humans of all ages, particularly malnourished children and those with compromised immune systems such as HIV/AIDS. This study investigated the therapeutic effects of acetylspiramycin and garlicin on Cryptosporidium infection in institutionalized male drug users receiving rehabilitative treatment. Examination of stool specimens from 903 drug users via modified acid-fast bacilli staining resulted in 172 positive cases. Among them 151 subjects consented to participate in a randomized trial of acetylspiramycin and garlicin in four groups: acetylspiramycin plus garlicin, acetylspiramycin only, garlicin only, and placebo control. The cryptosporidiosis rate was higher in younger subjects with longer drug use history than subjects who are older with shorter history of drug use. After two segments of treatments, 76.2% of the cases achieved negative test results, with the four groups achieving the rates of 92.1%, 76.7%, 72.2%, and 61.8%, respectively (χ(2) = 9.517, P = 0.023). These results indicate clinical potential of garlicin in conjunction with acetylspiramycin in treating cryptosporidiosis.

Indexed as

AdultAllyl CompoundsCoccidiostatsCryptosporidiosisDisulfidesDrug UsersHumansMaleSpiramycinYoung AdultacetylspiramycinAllyl CompoundsCoccidiostatsdiallyl disulfideDisulfidesSpiramycinAcetylspiramycinCryptosporidiumDrug userGarlicinRandomized controlled trialTherapeutic effects

Identifiers

PMID27120065
PMCPMC4846998
OpenAlexW2200249534

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.